BIOA
BioAge Labs, Inc.
Biotechnology
Market Cap$664M
5Y Perf.-11.3%
Compare Stocks
2 / 10Try these comparisons:
Stock Comparison
BIOA vs KYMR
Revenue, margins, valuation, and 5-year total return — side by side.
KYMR
Kymera Therapeutics, Inc.
Biotechnology
Market Cap$7.04B
5Y Perf.+82.3%
BIOA vs KYMR — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | BIOA | KYMR |
|---|---|---|
| Industry | Biotechnology | Biotechnology |
| Market Cap | $664M | $7.04B |
| Revenue (TTM) | $9M | $51M |
| Net Income (TTM) | $-81M | $-315M |
| Gross Margin | 99.2% | 33.2% |
| Operating Margin | -10.3% | -7.0% |
| Total Debt | $6M | $82M |
| Cash & Equiv. | $189M | $357M |
BIOA vs KYMR — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
BIOA
KYMR
| Stock | Sep 24 | May 26 | Return |
|---|---|---|---|
| BioAge Labs, Inc. (BIOA) | 100 | 88.8 | -11.3% |
| Kymera Therapeutics… (KYMR) | 100 | 182.3 | +82.3% |
Price return only. Dividends and distributions are not included.
Quick Verdict: BIOA vs KYMR
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: KYMR leads in 3 of 6 categories, making it the strongest pick for profitability and margin quality and capital preservation and lower volatility. BioAge Labs, Inc. is the stronger pick specifically for growth and revenue expansion and recent price momentum and sentiment. As sector peers, any of these can serve as alternatives in the same allocation.
BIOA
BioAge Labs, Inc.
The Growth Play
BIOA is the clearest fit if your priority is growth exposure and sleep-well-at-night.
- EPS growth 66.2%
- Lower volatility, beta 1.41, Low D/E 2.0%, current ratio 14.24x
- -13.3% revenue growth vs KYMR's -16.7%
Best for: growth exposure and sleep-well-at-night
KYMR
Kymera Therapeutics, Inc.
The Income Pick
KYMR carries the broadest edge in this set and is the clearest fit for income & stability and long-term compounding.
- beta 1.15
- 159.4% 10Y total return vs BIOA's 0.8%
- Beta 1.15, current ratio 10.47x
Best for: income & stability and long-term compounding
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | BIOA | -13.3% revenue growth vs KYMR's -16.7% |
| Quality / Margins | KYMR | -6.1% margin vs BIOA's -9.0% |
| Stability / Safety | KYMR | Beta 1.15 vs BIOA's 1.41 |
| Dividends | Tie | Neither stock pays a meaningful dividend |
| Momentum (1Y) | BIOA | +367.3% vs KYMR's +201.9% |
| Efficiency (ROA) | KYMR | -22.3% ROA vs BIOA's -25.5%, ROIC -24.9% vs -210.2% |
BIOA vs KYMR — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLKYMRLAGGINGBIOA
BIOABioAge Labs, Inc.
1leads
KYMRKymera Therapeutics, …
4leads
6 Total Categories
CATEGORYLEADERvs BIOAMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
KYMR3/5
Valuation MetricsMultiples, price ratios, and targets
BIOA2/3
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
KYMR5/9
Total Returns1Y, 3Y, 5Y total returns with dividends
KYMR4/6
Risk & VolatilityBeta, volatility, and downside exposure
KYMR2/2
Analyst OutlookRatings, price targets, and dividends
—
—
Income & Cash Flow (Last 12 Months)
KYMR leads this category, winning 3 of 5 comparable metrics.
Income & Cash Flow (Last 12 Months)
KYMR is the larger business by revenue, generating $51M annually — 5.7x BIOA's $9M. Profitability is closely matched — net margins range from -6.1% (KYMR) to -9.0% (BIOA).
| Metric | BIOABioAge Labs, Inc. | KYMRKymera Therapeuti… |
|---|---|---|
| RevenueTrailing 12 months | $9M | $51M |
| EBITDAEarnings before interest/tax | -$93M | -$352M |
| Net IncomeAfter-tax profit | -$81M | -$315M |
| Free Cash FlowCash after capex | -$82M | -$244M |
| Gross MarginGross profit ÷ Revenue | +99.2% | +33.2% |
| Operating MarginEBIT ÷ Revenue | -10.3% | -7.0% |
| Net MarginNet income ÷ Revenue | -9.0% | -6.1% |
| FCF MarginFCF ÷ Revenue | -9.2% | -4.7% |
| Rev. Growth (YoY)Latest quarter vs prior year | — | +55.5% |
| EPS Growth (YoY)Latest quarter vs prior year | +63.5% | +13.4% |
KYMR leads this category, winning 3 of 5 comparable metrics.
Valuation Metrics
BIOA leads this category, winning 2 of 3 comparable metrics.
Valuation Metrics
| Metric | BIOABioAge Labs, Inc. | KYMRKymera Therapeuti… |
|---|---|---|
| Market CapShares × price | $664M | $7.0B |
| Enterprise ValueMkt cap + debt − cash | $481M | $6.8B |
| Trailing P/EPrice ÷ TTM EPS | -8.24x | -23.38x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | — | — |
| Price / SalesMarket cap ÷ Revenue | 73.84x | 179.65x |
| Price / BookPrice ÷ Book value/share | 2.44x | 4.61x |
| Price / FCFMarket cap ÷ FCF | — | — |
BIOA leads this category, winning 2 of 3 comparable metrics.
Profitability & Efficiency
KYMR leads this category, winning 5 of 9 comparable metrics.
Profitability & Efficiency
KYMR delivers a -25.0% return on equity — every $100 of shareholder capital generates $-25 in annual profit, vs $-28 for BIOA. BIOA carries lower financial leverage with a 0.02x debt-to-equity ratio, signaling a more conservative balance sheet compared to KYMR's 0.05x. On the Piotroski fundamental quality scale (0–9), BIOA scores 5/9 vs KYMR's 4/9, reflecting solid financial health.
| Metric | BIOABioAge Labs, Inc. | KYMRKymera Therapeuti… |
|---|---|---|
| ROE (TTM)Return on equity | -27.9% | -25.0% |
| ROA (TTM)Return on assets | -25.5% | -22.3% |
| ROICReturn on invested capital | -2.1% | -24.9% |
| ROCEReturn on capital employed | -30.7% | -27.2% |
| Piotroski ScoreFundamental quality 0–9 | 5 | 4 |
| Debt / EquityFinancial leverage | 0.02x | 0.05x |
| Net DebtTotal debt minus cash | -$183M | -$275M |
| Cash & Equiv.Liquid assets | $189M | $357M |
| Total DebtShort + long-term debt | $6M | $82M |
| Interest CoverageEBIT ÷ Interest expense | -118.34x | -2119.53x |
KYMR leads this category, winning 5 of 9 comparable metrics.
Total Returns (Dividends Reinvested)
KYMR leads this category, winning 4 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in KYMR five years ago would be worth $21,049 today (with dividends reinvested), compared to $10,082 for BIOA. Over the past 12 months, BIOA leads with a +367.3% total return vs KYMR's +201.9%. The 3-year compound annual growth rate (CAGR) favors KYMR at 46.0% vs BIOA's 0.3% — a key indicator of consistent wealth creation.
| Metric | BIOABioAge Labs, Inc. | KYMRKymera Therapeuti… |
|---|---|---|
| YTD ReturnYear-to-date | +43.9% | +18.6% |
| 1-Year ReturnPast 12 months | +367.3% | +201.9% |
| 3-Year ReturnCumulative with dividends | +0.8% | +211.0% |
| 5-Year ReturnCumulative with dividends | +0.8% | +110.5% |
| 10-Year ReturnCumulative with dividends | +0.8% | +159.4% |
| CAGR (3Y)Annualised 3-year return | +0.3% | +46.0% |
KYMR leads this category, winning 4 of 6 comparable metrics.
Risk & Volatility
KYMR leads this category, winning 2 of 2 comparable metrics.
Risk & Volatility
KYMR is the less volatile stock with a 1.15 beta — it tends to amplify market swings less than BIOA's 1.41 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. KYMR currently trades 83.7% from its 52-week high vs BIOA's 76.9% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | BIOABioAge Labs, Inc. | KYMRKymera Therapeuti… |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.41x | 1.15x |
| 52-Week HighHighest price in past year | $24.00 | $103.00 |
| 52-Week LowLowest price in past year | $3.67 | $28.06 |
| % of 52W HighCurrent price vs 52-week peak | +76.9% | +83.7% |
| RSI (14)Momentum oscillator 0–100 | 43.6 | 46.3 |
| Avg Volume (50D)Average daily shares traded | 470K | 613K |
KYMR leads this category, winning 2 of 2 comparable metrics.
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
Wall Street rates BIOA as "Buy" and KYMR as "Buy". Consensus price targets imply 143.8% upside for BIOA (target: $45) vs 35.7% for KYMR (target: $117).
| Metric | BIOABioAge Labs, Inc. | KYMRKymera Therapeuti… |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy |
| Price TargetConsensus 12-month target | $45.00 | $117.06 |
| # AnalystsCovering analysts | 3 | 26 |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | — | — |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% |
Insufficient data to determine a leader in this category.
Key Takeaway
KYMR leads in 4 of 6 categories (Income & Cash Flow, Profitability & Efficiency). BIOA leads in 1 (Valuation Metrics).
Best OverallKymera Therapeutics, Inc. (KYMR)Leads 4 of 6 categories
Loading custom metrics...
BIOA vs KYMR: Frequently Asked Questions
8 questions · data-driven answers · updated daily
01Is BIOA or KYMR a better buy right now?
Analysts rate BioAge Labs, Inc.
(BIOA) a "Buy" — based on 3 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — BIOA or KYMR?
Over the past 5 years, Kymera Therapeutics, Inc.
(KYMR) delivered a total return of +110. 5%, compared to +0. 8% for BioAge Labs, Inc. (BIOA). Over 10 years, the gap is even starker: KYMR returned +159. 4% versus BIOA's +0. 8%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — BIOA or KYMR?
By beta (market sensitivity over 5 years), Kymera Therapeutics, Inc.
(KYMR) is the lower-risk stock at 1. 15β versus BioAge Labs, Inc. 's 1. 41β — meaning BIOA is approximately 23% more volatile than KYMR relative to the S&P 500. On balance sheet safety, BioAge Labs, Inc. (BIOA) carries a lower debt/equity ratio of 2% versus 5% for Kymera Therapeutics, Inc. — giving it more financial flexibility in a downturn.
04Which is growing faster — BIOA or KYMR?
On earnings-per-share growth, the picture is similar: BioAge Labs, Inc.
grew EPS 66. 2% year-over-year, compared to -23. 8% for Kymera Therapeutics, Inc.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
05Which has better profit margins — BIOA or KYMR?
Kymera Therapeutics, Inc.
(KYMR) is the more profitable company, earning -794. 4% net margin versus -896. 1% for BioAge Labs, Inc. — meaning it keeps -794. 4% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: KYMR leads at -891. 3% versus -1031. 5% for BIOA. At the gross margin level — before operating expenses — BIOA leads at 100. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Which pays a better dividend — BIOA or KYMR?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
07Is BIOA or KYMR better for a retirement portfolio?
For long-horizon retirement investors, Kymera Therapeutics, Inc.
(KYMR) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 1. 15), +159. 4% 10Y return). Both have compounded well over 10 years (KYMR: +159. 4%, BIOA: +0. 8%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
08What are the main differences between BIOA and KYMR?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.